Current Funding
UCI Start-Up Funds
UCI Cancer Center Pilot Grant- SCLC Treatment with an Immunoproteasome Prodrug
American Parkinson Disease Association- ByeTACs for Degrading Alpha-Synuclein Oligomers
UCI Cancer Center Pilot Grant- SCLC Treatment with an Immunoproteasome Prodrug
American Parkinson Disease Association- ByeTACs for Degrading Alpha-Synuclein Oligomers
Previous funding
NIH
R21GM131206- Development of Activity-Based Chemical Reporters to Differentiate Proteasome Isoforms in Cells
R01AI50847- Monitoring and Manipulating the Activity of the Immunoproteasome with Small Molecules
R01AI50847- Monitoring and Manipulating the Activity of the Immunoproteasome with Small Molecules
Showalter Trust Research Award
"Discovery of Proteasome Stimulators to Treat Diseases Associated with Protein Accumulation" 2017-2018
"Targeting Cancer Cells with an Immunoproteasome-Selective Prodrug Strategy" 2019-2020
"Targeting Cancer Cells with an Immunoproteasome-Selective Prodrug Strategy" 2019-2020
MCMP Research Enhancement Award
"Development of a high throughput FRET assay for screening natural products for 20S CP stimulators"
2017-2018
2017-2018
Purdue Cancer center grants
-American Cancer Society Institution Grant for New Investigators, 2016-2017
-Phase I Concept Award, Rpn-6 Inhibitors, 2017-2018
-Phase I Concept Award, Rpn-13 Inhibitors, 2019-2020
-Shared Resource Grant for Cryo-EM analysis of the proteasome and small molecules, 2019
-Phase II Concept Award, Rpn-6 Inhibitors 2018-2019
-Rpn-13 small molecule binders- 2019-2020 (Proteomics)
-Phase I Concept Award, Rpn-6 Inhibitors, 2017-2018
-Phase I Concept Award, Rpn-13 Inhibitors, 2019-2020
-Shared Resource Grant for Cryo-EM analysis of the proteasome and small molecules, 2019
-Phase II Concept Award, Rpn-6 Inhibitors 2018-2019
-Rpn-13 small molecule binders- 2019-2020 (Proteomics)
|
|